T. Rowe Price Associates’s Dianthus Therapeutics DNTH Stock Holding History

T. Rowe Price Associates’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$245M	Buy	2,514,946 +1,367,998	+119%	+$119M	0.02%	458
2026 Q1	$96.3M	Buy	1,146,948 +530,915	+86%	+$30.7M	0.01%	622
2025 Q4	$25.4M	Buy	616,033 +399,898	+185%	+$15.5M	﹤0.01%	1007
2025 Q3	$8.51M	Buy	216,135 +205,443	+1,921%	+$5.25M	﹤0.01%	1267
2025 Q2	$200K	Buy	10,692 +201	+2%	+$3.77K	﹤0.01%	2714
2025 Q1	$191K	Buy	10,491 +1,023	+11%	+$22.5K	﹤0.01%	2662
2024 Q4	$207K	Buy	9,468 +1,647	+21%	+$42.4K	﹤0.01%	2668
2024 Q3	$215K	Buy	+7,821	New	+$218K	﹤0.01%	2630
2021 Q3	–	Sell	-1,410	Closed	-$221K	–	2950
2021 Q2	$221K	Buy	+1,410	New	+$259K	﹤0.01%	2693

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

T. Rowe Price Associates's DNTH Position: Q2 2026 in Review

T. Rowe Price Associates increased its Dianthus Therapeutics (DNTH) stake by 119% in Q2 2026, buying an estimated $119M and bringing the position to 2,514,946 shares worth $245M. The position accounts for 0.02% of the portfolio, ranked #458.

T. Rowe Price Associates first reported a position in DNTH in Q2 2021 and has held it in 9 quarters since. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

T. Rowe Price Associates held 2,514,946 shares of Dianthus Therapeutics worth $245M as of Q2 2026.
T. Rowe Price Associates bought 1,367,998 Dianthus Therapeutics shares in Q2 2026, an estimated $119M.
Dianthus Therapeutics made up 0.02% of T. Rowe Price Associates's portfolio in Q2 2026, its #458 holding.
T. Rowe Price Associates first reported a position in Dianthus Therapeutics in Q2 2021 and has held it in 9 quarters since.
270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.